Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wrong answer. This public company chose to be non-reporting and use the Alternative Reporting Standard when Otiko took over the biz in 2014.
http://www.otcmarkets.com/stock/VDRM/profile
Why would they be "required" to be audited?
The article is from 2016.
ViaDerma doesn't audit financials...never have and likely never will.
With proper auditing they should be able to confirm their financials.
If the names of former associates of Otiko are okay to reveal, please place here. No need to give their contact info at this time. You can always PM me if you have that feature.
I didn't realize Otiko worked with anyone other than his family, the manufacturer of the products he may distribute, and the film producer Josten Theney.
It is cool to share info related to the company, it's officers, competitors and stock. If the info helps shed a light
TIA
I agree Panzer. Well advertised, low-float cannabis stocks with solid management focused on shareholder value WILL move up steadily and sometimes quickly.
I was in last year and left because there wasn't enough of a following. I'm glad VATE mentioned SIPC as the source of hemp for their emerging product line. It make me take a follow up look.
These are exciting times!
Would be smart to buy SIPC below .04
Oh, silly me, I thought that was a play on words using a 2016 news release. Still, the 17 news releases issued are worth reading if anyone wants to better understand this ticker.
I wasn't talking about the press in 2016 that was loaded with facts I was talking about the next press release and what he could title it
CGRA Poised for Break Out in Q2
When one reads the 17 news releases issued in 2016, it becomes clear they are loaded with facts, plans, actions taken, and many positive surprises like the bond company formation, new wells, and successful navigation of the bureaucratic processes involved in become a lessor of land to legal cannabis growers/producers.
yes, maybe Wright can title the next press as
CGRA poised for break out in Q2
The price history doesn't support numerous buyers at .12. Why is what happened over four years ago even a talking point today?
Look at how far they have come with their renewed focus on leasing to cannabis growers and producers, the formation of a bond company as an alternative to share selling and/or toxic financing, and, of course, the reworking of oil wells and new well leases.
We know the winter is a quiet time in the Wyoming oil and gas industry, and that the company was entering a new phase in their cannabis building plans over the winter.
I expect to hear the kitchen is complete. We know they began cannabis oil extraction services and will be able to explain that lease agreement, and numbers in the Q1 Report.
The updates will be professional and insightful and far from fluff news we see too often on crap tickers.
Most people I know bought this at .12, They are way under water
I have been collecting info on him. Will post when I have some time to organize it for presentation. There is nothing flattering that I can give anyone at this time.
I see this as a small family operation that entered the public market for funding. They have been issuing hundreds of millions of shares and reporting losses for three years. The news releases are likely issued by Otiko's brother Manny, a Director who owns a PR business. His wife is also a Director, although he did not disclose this relationship in his filing under the Disclosure requirement. She is named as an Officer using her maiden name.
Read my section of the iBox--the bottom portion with white background.
Can someone post some BIO info on this Dr.? Please
The bond company formed by CGrowth Capital funds international projects that include Powder River Resources' oilfield work in Wyoming. CGRA owns Powder River and the bond company. The bond company was thoroughly vetted by underwriters at Lloyd's of London.
www.cgrowthcapitalbond.com
If you read through the news releases and bond section at bottom of iBox, you will see credible and legal actions on many fronts.
CGRA doesn't issue news if it has no news to report. That is a positive action in my view.
CDEL has been shorting this for years. Some flippers have moved through on news. Many longs have been holding and plan to hold for much higher exit points.
Annual Report is due this week.
Just a thought. No news, bond money from another country. Everyone selling.
Can you explain what this message means? I have done extensive DD and have never seen a hint of embezzlement.
Maybe embezzlement?
DFCON is an educational conference focused on diabetic foot problems and solutions. Their website has everything anyone needs to know to understand the purpose. Livestream was available--perhaps for a price.
Dfcon.com
There is a stickie that mentions an acquaintance who attended. Otiko was in a room with about 20 other abstract poster presenters. He offered product samples to interested persons. He was not a speaker.
The product Otiko used in his abstract is available from at least one other competitor business under a different brand name. In a nearly identical formulation, Diabecline won an award in 2012 (see ibox table comparing Diabecline and Viabecline).
The underlying transdermal delivery system is patent-pending (Phillips/Keough). Otiko has a non-exclusive license to market and distribute Viabecline which is based on this system.
Read the last filing carefully to better understand this company. The Annual Report is due this week.
They also supply hemp to VATE for their Elev8 Coffee...also on Amazon. More products to follow.
SIPC also have a great partnership with KGK*, nice
move today
Otiko's businesses are related to his work as a foot and ankle doctor. I realize there is a green cross sign above the entrance to his two clinics--Coast to Coast and Laser Foot Doctor--pictured below. However, he has no license to grow, produce or retail cannabis in the State of California.
A forward looking news release means nothing here. History proves this to be true.
ViaDerma isn't a marijuana stock.
bigjay187 - The last news release was highly misleading. There is no patent application or award for vdrm or Otiko.
Filing an inexpensive provisional application for an invention simply sets an early filing date.
I recommend waiting to see if Otiko follows up with the required application, and whether the USPTO is willing to accept/publish that application.
Otiko has a long history of issuing news releases with inadequate info and hyped up info.
Here is another example of a misleading news release. Otiko announced Coast to Coast as a signed distributor a year ago. Well, he neglected to let his audience know he owns Coast to Coast and that it is actually his office in Reseda. Look at the link below to see my point.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129838164
I can agree the idiot theory may be in play--on Otiko's part, or should we say the IP thief theory is in play?
I read all the filings.
Wrong bigjay187. VDRM has no delivery system they "own." They license products based on the Phillips/Keough patent-pending delivery system.
Read the latest filing dated December 2016.
The products do not matter. Its the delivery system and VDRM owns that. $$$
If Big Pharma wanted to buy Phillips products/tech, why would they go through ViaDerma? That really makes no sense.
Otiko pays Phillips Company. Phillips doesnt pay Otiko. Phillips Company owns the products Otiko is trying to sell in a competitive market. Otiko has one non-exclusive manufacturing license for Viabecline, which essentially is the same product as Diabecline--Pharmacline's 2012 Edison Award Winner. It is manufactured at Phillips' facility in Oklahoma.
Otiko has non-exclusive distribution agreements for other Phillips products.
Keough (aka Pharmacline/Thru Pharma/Dakota Life Sciences) doesnt steal IP. He acquires IP. Here is a summary of his experience.
Mr. Keough is a graduate of Boston College Law School (J.D.), the Catholic University of America in Washington, D.C. (M.A. in Congressional Studies), and the United States Naval Academy at Annapolis (B.S.). His technology area of physics and his background as a submarine officer enable him to navigate comfortably in most technology fields, including medical devices and related sciences, manufacturing, optics, computer science, chemical coatings, formulations, and numerous others.
In the late 1980s, Mr. Keough was responsible for the patent accounts of numerous Asia-based manufacturing giants. He then went on to become widely known in the 1990s as an international expert on the phenomenon known as patent flooding. Mr. Keough played a pivotal role in the corporate-legal relationship of the mid-2000s which led to the largest medical device product release in history. This involved the first drug eluting cardiac stent to reach the United States market. From 2004-2008, Mr. Keough was Chief Patent Counsel at a public company, and contributed to the rapid rise of that company's market valution during his tenure.
With decades of experience in private practice and corporate settings, Mr. Keough has great insight into product life cycles and strategies of protection. He received a certificate in Finance for Non-Financial Executives from the Graduate School of the University of Chicago, and is quite aware of the financial pressures on corporate budgets. This awareness is at the heart of his founding of Law Offices National, P.A., to provide highly focused and efficient service in the patent arena- which has been a very costly area of patent expense to most businesses.
As a naval officer, Mr. Keough specialized in missile technology. He also commanded numerous U. S. naval forces in virtually all of the geographic regions of the world- retiring in 2004 at the naval rank of Captain. Mr. Keough also served as a Congressionally appointed civilian panel member charged with overseeing the conduct of the U.S. Department of Defense Threat Reduction Agency in the late 1990s and early 2000s. His area of responsibility related specifically to mitigating threats against the country from nuclear devices.
Phillips states they haven't licensed Tetrastem. Are you suggesting this will happen with vdrm?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129232062
Cease and Desist Letters deal with facts. That stopped Otiko from gaining further advantage.
Use this link to search for his license. He did get reprimanded for poor record keeping.
https://www.breeze.ca.gov/datamart/loginCADCA.do
Customers of Otikos business Coast to Coast? Did you look up that address in Google Maps?
False copyright document is noted in item 3 of linked interview.
http://wickedchannel.com/2017/02/wicked-channel-interview-joston-el-rey-theney-axeman-and-adam-k-2/
The merger with Dakota was finalized this month. Both companies have Annual Reports due end of month.
Kasten's history is not relevant to vdrm. Dakota's website is linked to Kasten website. They are rolling out their products this month through a fulfillment center in Connecticut.
Thank you for your contribution.
He is a foot and ankle doctor. That's it in a nutshell. He has no awards. Not sure how he became so elevated in stature simply by selling Phillips Company products through a non-exclusive license.
Otiko forged a copyright doc and sold movie online. That is a serious claim by Theney.
Two professionals have "distanced themselves" from Otiko. Keough and Justin Theney.
Although the partnership should ultimately result in more exposure for the film, it didn’t seem to create many fond memories for Joston. “The experience of co-producing this film with Blood Red Films hasn’t been the best one,” he explained, “so I’ve distanced myself from anything outside of my scope of work and divorced myself from the behind-the-scenes bullsh!t that left a skid mark on an otherwise awesome experience.”
There is no patent associated with this company or its CEO.
Thanks for helping get to the bottom of this patent issue. I haven't found anything to support the Keough claims you mentioned. I've seen accusations but they mean nothing without facts.
A state lawyers board would show sanctions. I'll dig into this angle.
I'm not here to support or defend Keough. Presenting objective facts is a work in progress. I welcome help in this area.
As stated previously, it may be Keough or the USPTO that provides answers.
I haven't communicated with either entity. I shared email excerpts between a shareholder and Keough and Phillips. Otiko is the silent one. That message is linked in iBox.
He had to pay full price because he didn't win the opportunity to pay half price. Viabecline is a new version of an older product known as Diabecline. Keoughs business Pharmacline won the Edison Award for Diabecline in 2012.
Pharmacline is the Patent Applicant on one of the two A1 numbers assigned to the delivery system.
Disclosure has never been his strong suit. Avoidance of questions surrounding the delivery system is notable. Questions may be better cleaned up through Keough and the USPTO. Phillips defers to Otiko.
Not true. Provisional apps alone never protect inventions. They set an early filing date that expires in one year if no further action is taken.
The doctor mislead many readers with that last headline. He should have stated his intention to file a patent application and when readers can expect that to happen
Stay in the moment with this guy. His forward looking messages need follow-up facts to make them real.
Agree on your perspective with Adams. Everyone deserves a second chance. I don't know how the Justice outcome impacts a biz outside of tax consulting.
No connection to cannabis sector at this time. Otiko claims he filed a provisional application with the USPTO. Until he files a patent application, his provisional action is meaningless. All that does is set an early filing date.
They have a non-exclusive license to manufacture a Phillips Company product known as Viabecline, and to distribute this product.
One announced distributor is owned by the Otiko's, Coast to Coast. A photo and Google map link have been shared of this Reseda Blvd location. It is where Otiko works.
The second announced distributor is BIOGENX, a business registered to the home address of Garrett Adams. Garrett, his brother, and father were busted for tax fraud in the millions of dollars. The link to the Justice Department’s notice is in the iBox and Stickied.
That's the million dollar question! Why are there so many application numbers leading up to the two A1 numbers assigned to the same invention?
It's good to see all the historical facts presented.
No contradiction on my part. The PR I linked was issued by the Patent Applicant Pharmacline, the company that was led by Keough, which is unrelated to vdrm.
It shows the product was around for many years.
Leading Diabetic Wound Care Specialist Dr. David G. Armstrong to Chair pharmaCline Wound Repair Advisory Team
http://www.businesswire.com/news/home/20130604005704/en/Leading-Diabetic-Wound-Care-Specialist-Dr.-David
Excellent piece of history regarding the original product based on the patent-pending delivery system (Phillips/Keough).
Diabecline and Viabecline are two very similar products.